5 minute read
Apr. 1, 2024

After Another Look, Vadadustat (VAFSEO) Becomes the Second HIF-PHD Inhibitor Approved by the FDA

vadadustat (VAFSEO)

oral HIF-PHD enzyme inhibitor Ph. III candidate for anemia in CKD carboxylic acid class of HIF-PHD inhibitors J. Pharmacol. Exp. Ther., Oct 1, 2022 Akebia Therapeutics, Cambridge, MA



Other molecules you may be interested in